1. Home
  2. BANX vs ACOG Comparison

BANX vs ACOG Comparison

Compare BANX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANX

ArrowMark Financial Corp.

N/A

Current Price

$19.48

Market Cap

202.4M

Sector

Finance

ML Signal

N/A

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

N/A

Current Price

$8.79

Market Cap

193.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BANX
ACOG
Founded
N/A
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
202.4M
193.6M
IPO Year
2013
2024

Fundamental Metrics

Financial Performance
Metric
BANX
ACOG
Price
$19.48
$8.79
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $18.00
AVG Volume (30 Days)
26.4K
★ 96.6K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 41.58
EPS
★ N/A
N/A
Revenue
N/A
★ $10,220,275.00
Revenue This Year
N/A
$153.46
Revenue Next Year
N/A
$85.72
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.45
$4.50
52 Week High
$22.50
$10.14

Technical Indicators

Market Signals
Indicator
BANX
ACOG
Relative Strength Index (RSI) 42.48 49.91
Support Level $19.31 $8.14
Resistance Level $19.78 $8.80
Average True Range (ATR) 0.31 0.46
MACD -0.00 0.06
Stochastic Oscillator 44.70 56.31

Price Performance

Historical Comparison
BANX
ACOG

About BANX ArrowMark Financial Corp.

ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: